PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2130441
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2130441
The urinalysis market is valued at around USD 4.88 billion in 2026 and is expected to reach USD 7.16 billion by 2031, reflecting an 8.0% growth rate. The rapid expansion of the elderly population is contributing to a higher incidence of age-related conditions, including diabetes and kidney and liver disorders. The increasing burden of these diseases is driving demand for routine diagnostic and monitoring tests, including metabolic, lipid, and renal and liver function assessments.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product, Test Type, Application, Technology, End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Urinalysis analyzers play an important role in screening and monitoring several such conditions, thereby supporting their adoption across hospitals, diagnostic laboratories, and other healthcare settings. Consequently, the growing geriatric population and associated disease burden are expected to remain significant drivers of urinalysis market growth.

"Consumables accounted for the largest share in the urinalysis market, by product, in 2025."
By product, the urinalysis market is segmented into consumables and instruments. The consumables segment accounts for the largest share of the urinalysis market. Recurring requirements and frequent replacement of consumables such as test strips, reagents, and controls are key drivers of its dominant share. Additionally, the availability of a wide range of consumables that cater to diverse urinalysis testing needs contributes to their widespread adoption. The development of advanced dipsticks with multiple test parameters further supports demand for urinalysis consumables.
"The biochemical assay segment accounted for the largest share in the urinalysis market, by technology, in 2025."
By technology, the urinalysis market is segmented into biochemical assays, flow cytometry, digital microscopy, and other technologies. In 2025, the biochemical assay segment led the urinalysis market. This segment's significant share is largely driven by the widespread use of reagent strips and immunoassay-based testing for routine disease screening, point-of-care diagnosis, home-based pregnancy and fertility testing, and preliminary detection of urinary tract infections, kidney diseases, diabetes, and liver diseases. Moreover, the low cost and ease of use of biochemical assays, their broad applicability across hospitals, diagnostic laboratories, and home care settings, the rising burden of chronic and infectious diseases requiring frequent urine testing, and continuous product innovation by key players in reagent strip and immunoassay formats are further contributing to the growth of this segment.
"Asia Pacific: Fastest-growing region in the urinalysis market."
The global urinalysis market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries. Asia Pacific is the fastest-growing regional market. This growth is driven by increasing government initiatives that promote disease awareness and early detection, rising per capita income, and the expansion of private healthcare infrastructure into rural and underserved areas. Additionally, the presence of emerging and high-growth markets across the region supports the adoption of urinalysis testing and diagnostic technologies.
The key players in the urinalysis market are Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Cardinal Health (US), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc.(US), Danaher Corporation (US), Abbott (US), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (Japan), Waters Corporation (US), Arkray, Inc. (Japan), Acon Laboratories, Inc. (US), 77 Elektronika KFT (Hungary), URIT Medical Electronic Group Co. Ltd. (China), Shenzhen, Mindray Bio-Medical Electronics Co., Ltd. (China), DIRUI Industrial Co. Ltd. (China), Biobase Group (China), ERBA Mannheim (UK), Alphatech Scientific (Peru), Teco Diagnostics (US), Analyticon Biotechnologies GmbH (Germany), Hivis Medical Technology Co., Ltd. (China), High Technology Inc. (US), Agappe Diagnostic Ltd. (India), Dialab GmbH (Austria), Quantimetrix (US), Biocare Corporation (Taiwan), Randox Laboratories Ltd. (Ireland), PZ Cormay S.A. (Poland), YD Diagnostics (South Korea), Contec Medical Systems Co., Ltd. (China), and Clarity Diagnostics LLC (US).
The scope of the report covers detailed information on the major factors, such as drivers, restraints, opportunities, and challenges, that influence the growth of the urinalysis market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, solutions, key strategies, acquisitions, and agreements. The report also covers new product launches and recent developments associated with the urinalysis market. Competitive analysis of upcoming startups in the urinalysis market ecosystem is included in this report.
The report will assist market leaders and new entrants in the urinalysis industry by providing estimated revenue figures for the overall market and its subsegments. It aims to help stakeholders understand the competitive landscape, enabling them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, opportunities, and challenges.